Trials / Completed
CompletedNCT02921984
Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The role of postoperative concurrent chemotherapy (CCT) has not been established for salivary gland tumors (SGTs). This prospective study was conducted to evaluate the feasibility and safety of customized CCT regimens based on the gene targets of SGTs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Docetaxel | Docetaxel only: 80 mg/m2 on day one, every 21 days if |
| RADIATION | Intensity-modulated radiotherapy | a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks |
| DRUG | Pemetrexed | Pemetrexed only: 500 mg/m2 on day one, every 21 days |
| DRUG | Cisplatin | Cisplatin only: 70 mg/m2 on day one to day three, every 21 days |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2016-12-01
- Completion
- 2017-08-01
- First posted
- 2016-10-03
- Last updated
- 2018-03-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02921984. Inclusion in this directory is not an endorsement.